Metabolic abnormalities and use of HIV-1 protease inhibitors [8]

Lancet

Volumn 352, Issue 9130, 1998, Pages 821-822

  Martinez, E ^a   Gatell, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VIRUS ENZYME;

FATTY ACID BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERINSULINEMIA; INSULIN DEGRADATION; INSULIN RESISTANCE; LETTER; LIPODYSTROPHY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0032487042     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60719-2     Document Type: Letter

References (5)

1. A Carr K Samaras DJ Chisholm DA Cooper Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 352 1998 1881 1883
2. RA Poorman AG Tomasselli RL Heinrikson FJ Kézdy A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base J Biol Chem 266 1991 14554 14561
3. S Bujalska IJ Kumar PM Steward Does central obesity reflect “Cushing's disease of the omentum”? Lancet 349 1997 1210 1213
4. RA Rizza LJ Mandarine J Genest BA Baker JE Gerich Production of insulin resistance by hyperinsulinaemia in man Diabetologia 28 1985 70 75
5. P Arner Not all fat is alike Lancet 351 1998 1301 1302